Valneva vaccine (VLA2001), developed by Valneva in France and Austria, is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine. Inactivated vaccines cannot replicate, so vaccinees cannot become infected with the virus.
VLA2001 received WHO Emergency Use Listing (EUL) on 18 August 2022. The WHO EUL process evaluates the quality of manufacturing along with all available safety and efficacy (or immunogenicity) data of the vaccine. All of the vaccines that have achieved WHO Emergency Use Listing can be considered safe and highly effective in preventing severe disease and hospitalization due to COVID-19.
VLA2001 is recommended in persons aged 18 and above.
Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations for use of COVID-19 vaccines:
https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials